Qingrong Wu
Research Subjects
Qingrong Wu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Yanting Chen
Department of Orthopedics, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China
3 shared publicationsLeying Lin
School of Basic Medicine, Gannan Medical University, Ganzhou, China
2 shared publicationsBing Wang
Department of Nephrology, Ganzhou People’s Hospital, Ganzhou, Jiangxi, China
1 shared publication- Gaorong Wu
Gannan Medical University
1 shared publication - Hongxing Huang
The Third Affiliated Hospital of Guangzhou University of Chinese Medicine
1 shared publication Jinlong Li
Ganzhou Liver Institute, Ganzhou Fifth People’s Hospital, Ganzhou, China
1 shared publication
Latest Publications
- Open Access
- 7 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
A cross-sectional study on associated factors of Chinese herbal medicine use in middle-aged and older adults with dyslipidaemia
The efficacy of Chinese herbal medicine (CHM) in treating dyslipidaemia has been demonstrated. However, the prevalence of CHM treatment and factors influencing its use in middle-aged and older patients with dyslipidaemia in China remain unclear. We aimed to investigate the prevalence and contributing factors of CHM use among middle-aged and older Chinese patients with dyslipidaemia. The data analyzed in this study were extracted from the fourth wave (2018) of the China Health and Retirement Longitudinal Study (CHARLS). Information on demographic and socioeconomic characteristics, health service use, health status, and history of CHM use was obtained. A logistic regression model was used to identify the key factors (demographics, health service use, and health status) that predict CHM use in the treatment of dyslipidaemia. In this cross-sectional study, a total of 4341 participants (middle-aged adults, 56.46%; older adults, 42.36%; males, 45.06%; females, 54.94%) with dyslipidaemia were included, and the prevalence of CHM use for dyslipidaemia was 14.08%. A logistic regression analysis revealed that compared with participants who did not use CHM, those who used CHM were more likely to have no income (OR 1.33; 95% CI 1.02, 1.74), visit traditional Chinese medicine hospitals (OR 2.85; 95% CI 1.71, 4.74), engage in self-treatment (OR 1.70; 95% CI 1.35, 2.13), report fair or poor health status (fair, OR 1.60; 95% CI 1.13, 2.26; poor, OR 1.99; 95% CI 1.36, 2.86), and a higher modified Chinese multimorbidity-weighted index (OR 1.06; 95% CI 1.03, 1.10). In the joint effect analysis, patients who visited a Chinese medicine hospital and had a stroke were more likely to use CHM (OR 6.90; 95% CI 2.08, 22.88) than those who did not visit a Chinese medicine hospital and did not have a stroke. In this study, the prevalence of CHM use was 14.08% among middle-aged and older patients with dyslipidaemia and was correlated with demographic factors, multimorbidity, and health service preferences in China. These findings suggest the need to integrate patient-specific factors into CHM-based dyslipidaemia management strategies.
- 7 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessA cross-sectional study on associated factors of Chinese herbal medicine use in middle-aged and older adults with dyslipidaemia
The efficacy of Chinese herbal medicine (CHM) in treating dyslipidaemia has been demonstrated. However, the prevalence of CHM treatment and factors influencing its use in middle-aged and older patients with dyslipidaemia in China remain unclear. We aimed to investigate the prevalence and contributing factors of CHM use among middle-aged and older Chinese patients with dyslipidaemia. The data analyzed in this study were extracted from the fourth wave (2018) of the China Health and Retirement Longitudinal Study (CHARLS). Information on demographic and socioeconomic characteristics, health service use, health status, and history of CHM use was obtained. A logistic regression model was used to identify the key factors (demographics, health service use, and health status) that predict CHM use in the treatment of dyslipidaemia. In this cross-sectional study, a total of 4341 participants (middle-aged adults, 56.46%; older adults, 42.36%; males, 45.06%; females, 54.94%) with dyslipidaemia were included, and the prevalence of CHM use for dyslipidaemia was 14.08%. A logistic regression analysis revealed that compared with participants who did not use CHM, those who used CHM were more likely to have no income (OR 1.33; 95% CI 1.02, 1.74), visit traditional Chinese medicine hospitals (OR 2.85; 95% CI 1.71, 4.74), engage in self-treatment (OR 1.70; 95% CI 1.35, 2.13), report fair or poor health status (fair, OR 1.60; 95% CI 1.13, 2.26; poor, OR 1.99; 95% CI 1.36, 2.86), and a higher modified Chinese multimorbidity-weighted index (OR 1.06; 95% CI 1.03, 1.10). In the joint effect analysis, patients who visited a Chinese medicine hospital and had a stroke were more likely to use CHM (OR 6.90; 95% CI 2.08, 22.88) than those who did not visit a Chinese medicine hospital and did not have a stroke. In this study, the prevalence of CHM use was 14.08% among middle-aged and older patients with dyslipidaemia and was correlated with demographic factors, multimorbidity, and health service preferences in China. These findings suggest the need to integrate patient-specific factors into CHM-based dyslipidaemia management strategies.
- 1 January 2026
- Published by Shanghai Institute of Organic Chemistry in Chinese Journal of Organic Chemistry
- Vol. 46 (2) , 523
Indium-Promoted Efficient Synthesis of Se -Aryl-2,2-dimethylbutaneselenoates
- 1 January 2026
- Published by Shanghai Institute of Organic Chemistry in Chinese Journal of Organic Chemistry
- Vol. 46 (2) , 523
Indium-Promoted Efficient Synthesis of Se -Aryl-2,2-dimethylbutaneselenoates
- Open Access
- 22 September 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1625873
Burden of drug use disorders from 1990 to 2021 and projection to 2050 in China: findings from the 2021 global burden of disease study
Background: Drug use disorders (DUDs) represent a major public health challenge globally, including China. This study investigated the impact of DUDs in China over the past 3 decades and examined the long-term trends in their epidemiological characteristics.Methods: Data were obtained from the 2021 Global Burden of Disease (GBD) study. The burden of DUDs was assessed through Disability-Adjusted Life Years (DALYs), Years of Life Lost (YLLs), and Years Lived with Disability (YLDs). Joinpoint analysis was used to compute the Average Annual Percentage Change (AAPC), and Age-Period-Cohort analyses were conducted to illustrate trends in the burden of DUDs. A Bayesian Age-Period-Cohort model was fitted to forecast the anticipated burden.Results: From 1990 to 2021, the Age-Standardized Incidence Rate (ASIR), Age-Standardized Prevalence Rate (ASPR), and Age-Standardized Mortality Rate (ASMR) for DUDs in China demonstrated a consistent decline, with AAPC values of −0.76% (95% confidence interval [CI]: 0.83% to −0.69%), −1.05% (95% CI: 1.25% to −0.84%), and −4.41% (95% CI: 4.75% to −4.08%), respectively. Analysis of temporal trends indicated that the ASIR and ASPR for DUDs peaked between 1990 and 2000, followed by a variable decline, with a minor uptick noted from 2015 to 2021. The age-standardized DALY rates reached their zenith during 1990–2000. Additionally, analysis by age group indicated that from 1990 to 2021, the ASIR and ASPR for DUDs were highest among individuals aged 20–24 years, followed by a fluctuating decline. Gender-based analysis indicated that throughout this period, disease burden indicators for males consistently surpassed those for females. Projections from the Bayesian Age-Period-Cohort model suggest the ASIR will increase by 3.91% annually from 2022 to 2050, with growth rates of 4.54% for males and 3.25% for females.Conclusion: Between 1990 and 2021, China experienced a decline in the overall burden of DUDs. However, high incidence and prevalence rates persist, signifying an ongoing significant impact. By 2050, both incidence and prevalence rates of drug abuse are expected to increase significantly, necessitating a focus on the male population and the development of targeted prevention and intervention strategies.
- 22 September 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1625873
Open AccessBurden of drug use disorders from 1990 to 2021 and projection to 2050 in China: findings from the 2021 global burden of disease study
Background: Drug use disorders (DUDs) represent a major public health challenge globally, including China. This study investigated the impact of DUDs in China over the past 3 decades and examined the long-term trends in their epidemiological characteristics.Methods: Data were obtained from the 2021 Global Burden of Disease (GBD) study. The burden of DUDs was assessed through Disability-Adjusted Life Years (DALYs), Years of Life Lost (YLLs), and Years Lived with Disability (YLDs). Joinpoint analysis was used to compute the Average Annual Percentage Change (AAPC), and Age-Period-Cohort analyses were conducted to illustrate trends in the burden of DUDs. A Bayesian Age-Period-Cohort model was fitted to forecast the anticipated burden.Results: From 1990 to 2021, the Age-Standardized Incidence Rate (ASIR), Age-Standardized Prevalence Rate (ASPR), and Age-Standardized Mortality Rate (ASMR) for DUDs in China demonstrated a consistent decline, with AAPC values of −0.76% (95% confidence interval [CI]: 0.83% to −0.69%), −1.05% (95% CI: 1.25% to −0.84%), and −4.41% (95% CI: 4.75% to −4.08%), respectively. Analysis of temporal trends indicated that the ASIR and ASPR for DUDs peaked between 1990 and 2000, followed by a variable decline, with a minor uptick noted from 2015 to 2021. The age-standardized DALY rates reached their zenith during 1990–2000. Additionally, analysis by age group indicated that from 1990 to 2021, the ASIR and ASPR for DUDs were highest among individuals aged 20–24 years, followed by a fluctuating decline. Gender-based analysis indicated that throughout this period, disease burden indicators for males consistently surpassed those for females. Projections from the Bayesian Age-Period-Cohort model suggest the ASIR will increase by 3.91% annually from 2022 to 2050, with growth rates of 4.54% for males and 3.25% for females.Conclusion: Between 1990 and 2021, China experienced a decline in the overall burden of DUDs. However, high incidence and prevalence rates persist, signifying an ongoing significant impact. By 2050, both incidence and prevalence rates of drug abuse are expected to increase significantly, necessitating a focus on the male population and the development of targeted prevention and intervention strategies.
- Open Access
- 22 May 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1482228
Prevalence and factors associated with Chinese herbal medicine use among middle-aged and older Chinese adults with diabetes mellitus
Background: The effectiveness of traditional Chinese medicine (TCM) in treating diabetes has been confirmed in China and globally. However, research on the use of Chinese herbal medicine (CHM) among middle-aged and elderly patients with diabetes and its associated factors is limited. This study aims to explore the prevalence of CHM use among these patients and its associated factors.Methods: This study utilized data from the China Health and Retirement Longitudinal Study, which covers Chinese adults aged ≥45 years. A cross-sectional analysis was conducted on 3,347 participants who used CHM for diabetes treatment. Multivariate logistic regression models were employed to identify key factors (including demographic characteristics, health status, and healthcare utilization) that predict CHM use among patients with diabetes.Results: The prevalence of CHM use for diabetes was 10.8% among middle-aged and older Chinese patients with diabetes. Compared to patients with diabetes who did not use CHM, those who did were more likely to be older (OR = 1.31; 95% CI = 1.04, 1.65), visit TCM hospitals (OR = 1.24; 95% CI = 1.01, 1.53), engage in self-treatment (OR = 1.90; 95% CI = 1.38, 2.61), have kidney disease (OR = 1.50; 95% CI = 1.05, 2.14), and have asthma (OR = 2.19; 95% CI = 1.29, 3.70). In the combined effect analysis, patients with both kidney disease and asthma were most likely to use CHM (OR = 4.20; 95% CI = 1.93, 9.14).Conclusion: The prevalence of CHM use among middle-aged and elderly Chinese patients with diabetes was relatively low, and was associated with specific health conditions and healthcare behaviors.
- 22 May 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1482228
Open AccessPrevalence and factors associated with Chinese herbal medicine use among middle-aged and older Chinese adults with diabetes mellitus
Background: The effectiveness of traditional Chinese medicine (TCM) in treating diabetes has been confirmed in China and globally. However, research on the use of Chinese herbal medicine (CHM) among middle-aged and elderly patients with diabetes and its associated factors is limited. This study aims to explore the prevalence of CHM use among these patients and its associated factors.Methods: This study utilized data from the China Health and Retirement Longitudinal Study, which covers Chinese adults aged ≥45 years. A cross-sectional analysis was conducted on 3,347 participants who used CHM for diabetes treatment. Multivariate logistic regression models were employed to identify key factors (including demographic characteristics, health status, and healthcare utilization) that predict CHM use among patients with diabetes.Results: The prevalence of CHM use for diabetes was 10.8% among middle-aged and older Chinese patients with diabetes. Compared to patients with diabetes who did not use CHM, those who did were more likely to be older (OR = 1.31; 95% CI = 1.04, 1.65), visit TCM hospitals (OR = 1.24; 95% CI = 1.01, 1.53), engage in self-treatment (OR = 1.90; 95% CI = 1.38, 2.61), have kidney disease (OR = 1.50; 95% CI = 1.05, 2.14), and have asthma (OR = 2.19; 95% CI = 1.29, 3.70). In the combined effect analysis, patients with both kidney disease and asthma were most likely to use CHM (OR = 4.20; 95% CI = 1.93, 9.14).Conclusion: The prevalence of CHM use among middle-aged and elderly Chinese patients with diabetes was relatively low, and was associated with specific health conditions and healthcare behaviors.
- Open Access
- 22 June 2024
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 25 (1) , 1-9
Association between dietary folate intake and the risk of osteoporosis in adults: a cross-sectional study
Background: Increased intake of specific vitamins has been linked to a decreased prevalence of osteoporosis. However, the association between dietary folate intake and the risk of osteoporosis in the general population remains incompletely understood. Therefore, we aimed to determine the association between dietary folate intake and the risk of osteoporosis in the general population of the USA. Methods: In this cross-sectional study, data from the National Health and Nutrition Examination Survey (2017–2020) were collected. Osteoporosis was considered to be indicated by a bone mineral density greater than 2.5 standard deviations below the mean of the young adult reference group. Dietary folate intake was measured by a 24-hour dietary recall. Multivariate logistic regression models and restricted cubic spline models were used. Results: The study included 2297 participants (mean age: 63.69 ± 0.35 years), 49.92% of whom were female. In the general population, increased dietary folate intake was directly associated with a decreased risk of osteoporosis (P for trend = 0.005). In the age > 60 years and female subgroups, folate intake was inversely associated with the risk of osteoporosis (P for trend < 0.001). The dose‒response curve suggested that this association was nonlinear (P for nonlinearity = 0.015). Conclusions: Our cross-sectional study provides initial insights into the inverse association between dietary folate intake and the risk of osteoporosis in the general U.S. population. Further research is needed to confirm these associations.
- 22 June 2024
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 25 (1) , 1-9
Open AccessAssociation between dietary folate intake and the risk of osteoporosis in adults: a cross-sectional study
Background: Increased intake of specific vitamins has been linked to a decreased prevalence of osteoporosis. However, the association between dietary folate intake and the risk of osteoporosis in the general population remains incompletely understood. Therefore, we aimed to determine the association between dietary folate intake and the risk of osteoporosis in the general population of the USA. Methods: In this cross-sectional study, data from the National Health and Nutrition Examination Survey (2017–2020) were collected. Osteoporosis was considered to be indicated by a bone mineral density greater than 2.5 standard deviations below the mean of the young adult reference group. Dietary folate intake was measured by a 24-hour dietary recall. Multivariate logistic regression models and restricted cubic spline models were used. Results: The study included 2297 participants (mean age: 63.69 ± 0.35 years), 49.92% of whom were female. In the general population, increased dietary folate intake was directly associated with a decreased risk of osteoporosis (P for trend = 0.005). In the age > 60 years and female subgroups, folate intake was inversely associated with the risk of osteoporosis (P for trend < 0.001). The dose‒response curve suggested that this association was nonlinear (P for nonlinearity = 0.015). Conclusions: Our cross-sectional study provides initial insights into the inverse association between dietary folate intake and the risk of osteoporosis in the general U.S. population. Further research is needed to confirm these associations.